##### Table of Contents









UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549





FORM 10-K/A


(Amendment No. 1)


(Mark One)




| |   |                                                                                         
| | - | ----------------------------------------------------------------------------------------
| | þ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For
the fiscal year ended December 31, 2005


OR




| |   |                                                                                       
| | - | --------------------------------------------------------------------------------------
| | o | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-15875


King Pharmaceuticals, Inc.




|                                                                                |  |                                         
|------------------------------------------------------------------------------- |  | ----------------------------------------
|Tennessee                                                                       |  | 54-1684963                              
|(State or other jurisdiction of
    incorporation or organization)              |  | (I.R.S. Employer
    Identification No.)
|                                                                               
|501 Fifth Street
    Bristol, Tennessee(Address of Principal Executive Offices) |  | 37620(Zip Code)                         

(423) 989-8000




|                                                                |  |                                            
|--------------------------------------------------------------- |  | -------------------------------------------
|(Title of each class)                                           |  | (Name of each exchange on which registered)
|                                                                |  |                                            
|Common Stock and Associated
    Preferred Stock Purchase Rights |  | New York Stock Exchange                    



None


þ o


o þ


þ o


S-K 10-K 10-K. þ


12b-2


þ o o


12b-2 o þ




Documents Incorporated by Reference:


Certain information required in Part III of this Annual
Report on Form 10-K is incorporated


by reference from the registrants Proxy Statement for
its 2006 annual meeting of shareholders.










---

TABLE OF CONTENTS



|                                              |                                                   |  |  |  |  |  |  | 
|--------------------------------------------- | ------------------------------------------------- |  |  |  |  |  |  | 
|EXPLANATORY NOTE                             
|PART IV                                      
|                                              | Item 15. Exhibits, Financial Statement Schedules.
|SIGNATURES                                   
|EX-23.1 CONSENT OF PRICEWATERHOUSECOOPERS LLP
|EX-31.1 SECTION 302 CERTIFICATION OF THE CEO 
|EX-31.2 SECTION 302 CERTIFICATION OF THE CFO 
|EX-32.1 SECTION 906 CERTIFICATION OF THE CEO 
|EX-32.2 SECTION 906 CERTIFICATION OF THE CFO 



---



##### Table of Contents






EXPLANATORY NOTE


10-K 10-K




12b-15




---



##### Table of Contents






PART IV







|         |                                         
|-------- | ----------------------------------------
|Item 15. | Exhibits, Financial Statement Schedules.





|        |    |    |  |             |  |                                                                                                      
|------- | -- | -- |  | ----------- |  | -----------------------------------------------------------------------------------------------------
|Exhibit |    |    |  |            
|Number  |    |    |  | Description
|        |    |    |  |            
|        | 23 | .1 |  |            |  | Consent of PricewaterhouseCoopers LLP.                                                               
|       
|        | 31 | .1 |  |            |  | Certificate of Chief Executive Officer Pursuant to
    Section 302 of the Sarbanes-Oxley Act of 2002.
|       
|        | 31 | .2 |  |            |  | Certificate of Chief Financial Officer Pursuant to
    Section 302 of the Sarbanes-Oxley Act of 2002.
|       
|        | 32 | .1 |  |            |  | Certificate of Chief Executive Officer Pursuant to
    Section 906 of the Sarbanes-Oxley Act of 2002.
|       
|        | 32 | .2 |  |            |  | Certificate of Chief Financial Officer Pursuant to
    Section 906 of the Sarbanes-Oxley Act of 2002.





---



##### Table of Contents






SIGNATURES






| |                           
| | --------------------------
| | KING PHARMACEUTICALS, INC.



| |     |                      
| | --- | ---------------------
| | By: | /s/ Brian A. Markison

| |                                      
| | -------------------------------------
| |                                      
| | Brian A. Markison                    
| | President and Chief Executive Officer





|                                           |  |                                                                          |  |               |  | 
|------------------------------------------ |  | ------------------------------------------------------------------------ |  | ------------- |  | 
|Signature                                  |  | Capacity                                                                 |  | Date         
|                                           |  |                                                                          |  |              
|                                          
|/s/ Brian A. MarkisonBrian A. Markison     |  | President, Chief Executive Officer and Director                          |  | March 8, 2006
|                                          
|/s/ Joseph SquicciarinoJoseph Squicciarino |  | Chief Financial Officer (principal financial and accounting
    officer) |  | March 8, 2006

II-1